foscarnet has been researched along with Acute Kidney Failure in 17 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 9.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 5.72 | Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study. ( Hino, M; Inose, R; Nagayama, K; Nanno, S; Sugimoto, T; Takahashi, K; Takahashi, M, 2022) |
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 5.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "The significance of acute renal insufficiency has grown in the past decade." | 2.44 | [Renal insufficiency caused by medicines, diagnostic processes, toxins]. ( Szegedi, J, 2007) |
| "Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 1.72 | Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study. ( Hino, M; Inose, R; Nagayama, K; Nanno, S; Sugimoto, T; Takahashi, K; Takahashi, M, 2022) |
| "Foscarnet is an antiviral agent widely used in the treatment of cytomegalovirus (CMV) infection." | 1.31 | Removal of Foscarnet by hemodialysis using dialysate-side values. ( Gambertoglio, JG; Ing, TS; Leehey, DJ; Patel, SB; Popli, A; Sam, R, 2000) |
| "Since incremental increases in residual clearance of 30% or more generally will result in clinically significant changes in a drug's serum concentration, foscarnet dosage needs to be individualized for patients receiving peritoneal dialysis." | 1.29 | Disposition of foscarnet during peritoneal dialysis. ( Akers, A; Alexander, AC; Aweeka, FT; Fraley, DS; Matzke, GR, 1996) |
| "Foscarnet is a pyrophosphate analogue that has been successfully used in severe cytomegalovirus (CMV) infections." | 1.28 | Foscarnet nephrotoxicity: mechanism, incidence and prevention. ( Baumelou, A; Beaufils, H; Danis, M; Deray, G; Dohin, E; Gentilini, M; Katlama, C; Levaltier, B; Martinez, F; Rozenheim, M, 1989) |
| "Foscarnet (FC) is a new antiviral agent which has been recently proposed for the treatment of severe cytomegalovirus (CMV) infections in immunocompromised patients." | 1.27 | Acute renal failure induced by foscarnet: 4 cases. ( Baumelou, A; Cacoub, P; Deray, G; Gentilini, M; Jacobs, C; Le Hoang, P; Rousselie, R; Rozenbaum, W; Soubrie, C, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Inose, R | 1 |
| Takahashi, K | 1 |
| Takahashi, M | 1 |
| Sugimoto, T | 1 |
| Nanno, S | 1 |
| Hino, M | 1 |
| Nagayama, K | 1 |
| Kwan, LP | 1 |
| Mok, MM | 1 |
| Choy, BY | 1 |
| Chan, TM | 1 |
| Didsbury, MS | 1 |
| Mackie, FE | 1 |
| Kennedy, SE | 1 |
| Joannidis, M | 1 |
| Francisci, D | 1 |
| Marroni, M | 1 |
| Morosi, S | 1 |
| Canovari, B | 1 |
| Belfiori, B | 1 |
| Stagni, G | 1 |
| Baldelli, F | 1 |
| Szegedi, J | 1 |
| Morales, JM | 1 |
| Muñoz, MA | 1 |
| Fernández Zataraín, G | 1 |
| García Cantón, C | 1 |
| García Rubiales, MA | 1 |
| Andrés, A | 1 |
| Aguado, JM | 1 |
| Gonzalez Pinto, I | 1 |
| Navarro, JF | 1 |
| Mora, C | 1 |
| Gallego, E | 1 |
| García, J | 1 |
| Alexander, AC | 1 |
| Akers, A | 1 |
| Matzke, GR | 1 |
| Aweeka, FT | 1 |
| Fraley, DS | 1 |
| Chatelain, E | 1 |
| Deminière, C | 1 |
| Lacut, JY | 1 |
| Potaux, L | 1 |
| Zanetta, G | 1 |
| Maurice-Estepa, L | 1 |
| Mousson, C | 1 |
| Justrabo, E | 1 |
| Daudon, M | 1 |
| Rifle, G | 1 |
| Tanter, Y | 1 |
| Sam, R | 1 |
| Patel, SB | 1 |
| Popli, A | 1 |
| Leehey, DJ | 1 |
| Gambertoglio, JG | 2 |
| Ing, TS | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Deray, G | 3 |
| Martinez, F | 1 |
| Katlama, C | 1 |
| Levaltier, B | 1 |
| Beaufils, H | 1 |
| Danis, M | 1 |
| Rozenheim, M | 1 |
| Baumelou, A | 3 |
| Dohin, E | 1 |
| Gentilini, M | 2 |
| Cacoub, P | 2 |
| Le Hoang, P | 2 |
| Rozenbaum, W | 1 |
| Soubrie, C | 2 |
| Rousselie, R | 1 |
| Jacobs, C | 2 |
| Rousselie, F | 1 |
| Morer, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
3 reviews available for foscarnet and Acute Kidney Failure
| Article | Year |
|---|---|
A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients.
Topics: Acute Kidney Injury; Adolescent; Amphotericin B; Biomarkers; Child; Cyclosporine; Foscarnet; Glomeru | 2015 |
Drug-induced renal failure in the ICU.
Topics: Acute Kidney Injury; Adenine; Amphotericin B; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Age | 2004 |
[Renal insufficiency caused by medicines, diagnostic processes, toxins].
Topics: Acetaminophen; Acute Kidney Injury; Aminoglycosides; Amphotericin B; Angiotensin II Type 1 Receptor | 2007 |
1 trial available for foscarnet and Acute Kidney Failure
| Article | Year |
|---|---|
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin | 1995 |
13 other studies available for foscarnet and Acute Kidney Failure
| Article | Year |
|---|---|
Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study.
Topics: Acute Kidney Injury; Foscarnet; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Retrospe | 2022 |
Acute kidney injury in a renal transplant recipient due to concomitant use of vancomycin and foscarnet.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Antiviral Agents; Foscarnet; Humans; Kidney Trans | 2017 |
Fatal haemolytic uraemic syndrome in an AIDS patient with disseminated adenovirus and cytomegalovirus co-infection.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenovirus Infections, Human; Colitis; Cyto | 2006 |
Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Cyclosporine; Cytomegalovirus Infections; Drug Interac | 1995 |
Acute renal failure associated with foscarnet therapy.
Topics: Acute Kidney Injury; Antiviral Agents; Foscarnet; Humans | 1996 |
Disposition of foscarnet during peritoneal dialysis.
Topics: Acute Kidney Injury; Adult; Cytomegalovirus Infections; Foscarnet; Half-Life; Humans; Male; Peritone | 1996 |
Severe renal failure and polyneuritis induced by foscarnet.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Female; Foscarnet; Herpesviridae Infections; Humans; I | 1998 |
Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation.
Topics: Acute Kidney Injury; AIDS-Associated Nephropathy; Antiviral Agents; Cytomegalovirus Infections; Fosc | 1999 |
Removal of Foscarnet by hemodialysis using dialysate-side values.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Antiviral Agents; Cytomegalovirus Infections; Drug | 2000 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
Foscarnet nephrotoxicity: mechanism, incidence and prevention.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Creatinine; Cytomegalovirus Infections; Fluid Ther | 1989 |
Acute renal failure induced by foscarnet: 4 cases.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Chorioretinitis; C | 1988 |
Foscarnet-induced acute renal failure and effectiveness of haemodialysis.
Topics: Acute Kidney Injury; Female; Foscarnet; Humans; Middle Aged; Organophosphorus Compounds; Phosphonoac | 1987 |